Preclinical Evidence and Clinical Pharmacology
Preclinical studies and clinical pharmacologic evaluations to understand the pathophysiologic mechanisms, therapeutic targets, and pharmacologic profile of an IV CDK4/6 inhibitor for chemotherapy-induced myelosuppression in extensive-stage lung cancer, including assessments of mechanism of action, pharmacokinetics, and pharmacodynamics.
This section includes links to Pharmacosmos sponsored-publications and selected Pharmacosmos posters. Information contained in these publications may include information that is inconsistent with the FDA approved use of product(s). Pharmacosmos does not recommend the use of its products in a manner that is inconsistent with FDA-approved labeling. Additionally, the content contained in this section is subject to congress copyright permissions.
*Trilaciclib was developed by G1 Therapeutics which is now subsidiary of Pharmacosmos Therapeutics
May 2021 | Cancer Chemother Pharmacol
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
Li C, Hart L, Owonikoko TK, et al.
October 2020 | J Immunother Cancer
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Lai AY, Sorrentino JA, Dragnev KH, et al.
November 13-16, 2018 | 30th EORTC-NCI-AACR Symposium (Poster)
Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
Sorrentino JA, Bisi JE, Thompson D, et al.
April 2017 | Sci Transl Med
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He S, Roberts PJ, Sorrentino JA, et al.
May 2016 | Mol Cancer Ther
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Bisi JE, Sorrentino JA, Roberts PJ, et al.
November 29-December 2, 2016 | 28th EORTC-NCI-AACR Symposium (Poster)
Trilaciclib (G1T28), a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
Roberts PJ, He S, Schvartsman G, et al.
May 29-June 2, 2015 | 2015 ASCO Annual Meeting (Poster)
Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression
Roberts PJ, White HS, Sorrentino JA, et al.